SAM
LXRX icon

Shell Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Shell Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-33,769
Closed -$467K – 1096
2016
Q4 		$467K Buy
+33,769
New +$542K 0.01% 901

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Shell Asset Management's LXRX Position: Q1 2017 in Review

Shell Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2017, closing a stake of 33,769 shares — an estimated $467K sold.

Shell Asset Management first reported a position in LXRX in Q4 2016 and held it in 1 quarter. The position peaked at $467K in Q4 2016. 137 funds tracked by Wall St. Rank hold LXRX as of Q1 2017.

  • Shell Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Shell Asset Management sold 33,769 Lexicon Pharmaceuticals shares in Q1 2017, an estimated $467K.
  • Shell Asset Management first reported a position in Lexicon Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Shell Asset Management's Lexicon Pharmaceuticals position peaked at $467K in Q4 2016.
  • 137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2017.

Based on Shell Asset Management's 13F filing for Q1 2017, filed 26 Apr 2017.